Kymera Therapeutics, Inc. Common Stock

KYMR XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

5.9B

Short interest (May 15)

12.2%

Net Short (Jun 03 ): 0.2%

Borrow Fee

0.40%

↓ 1.4%

Available Shares

500K

↑ 28.2%

Price Chart

Company Overview

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001815442

Asset Type: CS

Market Data

Market Cap: $5,864,143,448

Employees: 253

Status: Active

Short Interest

Current Borrow Fee 0.40%

Range: 0.40% - 0.40%

Available Shares 500K

Range: 450K - 450K

Recent Changes

Fee Change: ↓ 0.1%

Available Change: ↓ 10.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime